title: Noninterferon-based adjuvant therapy for high-risk melanoma.
abstract: High-dose interferon is the only treatment approved by the FDA for adjuvant therapy of melanoma. However, its efficacy in this setting is questionable and its administration is associated with considerable toxicity. Many new agents are being tested clinically that hold the promise of greater efficacy and less toxicity but none of these have yet shown efficacy in controlled trials. These include biologics such as vaccines, cytokines, monoclonal antibodies, gene transfer, cellular therapies and angiogenesis inhibitors as well as chemotherapy combinations.
authors.affiliation: Northern California Melanoma Center, 900 Hyde Street, San Francisco, CA 94109, USA. Lynn@DrSpitler.com
authors.forename: Lynn E
authors.initials: LE
authors.lastname: Spitler
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D016207:Cytokines / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016207:Cytokines; D007372:Interferons